You are here: Home » PTI Stories » National » News
Business Standard

Glenmark Pharma gets USFDA nod for skin treatment ointment

Health Medical Pharma

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals on Friday said it has received final approval from the US health regulator for Pimecrolimus Cream, used to treat skin conditions such as eczema.

The approved product is a generic version of Elidel Cream, 1 per cent, of Bausch Health US, LLC.

Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the the United States Food and Drug Administration (USFDA) for Pimecrolimus Cream, 1 per cent, the company said in a BSE filing.

Citing IQVIA sales data, Glenmark said, Elidel Cream achieved annual sales of approximately USD 198.8 million in the 12-month period ended July 2019.

The company said its current portfolio consists of 160 products authorised for distribution in the US and 55 Abbreviated New Drug Application's (ANDA) pending approval with the USFDA.

Shares of Glenmark Pharma were trading 0.22 per cent higher at Rs 384.35 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, August 30 2019. 10:35 IST